BR112015031835B1 - Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético - Google Patents
Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético Download PDFInfo
- Publication number
- BR112015031835B1 BR112015031835B1 BR112015031835-5A BR112015031835A BR112015031835B1 BR 112015031835 B1 BR112015031835 B1 BR 112015031835B1 BR 112015031835 A BR112015031835 A BR 112015031835A BR 112015031835 B1 BR112015031835 B1 BR 112015031835B1
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- formula
- disease
- hyperkinetic movement
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382230 | 2013-06-19 | ||
| EP13382230.4 | 2013-06-19 | ||
| PCT/EP2014/062786 WO2014202646A1 (en) | 2013-06-19 | 2014-06-18 | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015031835A2 BR112015031835A2 (pt) | 2017-07-25 |
| BR112015031835A8 BR112015031835A8 (pt) | 2019-12-31 |
| BR112015031835B1 true BR112015031835B1 (pt) | 2022-12-13 |
Family
ID=48672545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015031835-5A BR112015031835B1 (pt) | 2013-06-19 | 2014-06-18 | Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9789072B2 (https=) |
| EP (1) | EP3010543B1 (https=) |
| JP (1) | JP6476174B2 (https=) |
| KR (1) | KR102254542B1 (https=) |
| CN (1) | CN105658238B (https=) |
| AU (1) | AU2014283319B2 (https=) |
| BR (1) | BR112015031835B1 (https=) |
| CA (1) | CA2915811C (https=) |
| CL (1) | CL2015003679A1 (https=) |
| DK (1) | DK3010543T3 (https=) |
| ES (1) | ES3053333T3 (https=) |
| IL (1) | IL243192B (https=) |
| MX (1) | MX366353B (https=) |
| PL (1) | PL3010543T3 (https=) |
| PT (1) | PT3010543T (https=) |
| RU (1) | RU2685502C2 (https=) |
| SG (1) | SG11201510451RA (https=) |
| WO (1) | WO2014202646A1 (https=) |
| ZA (1) | ZA201600312B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41557A (fr) | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
| ES3024958T3 (en) * | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790165A (fr) * | 1971-12-14 | 1973-02-15 | Parke Davis & Co | Nouveaux aminoalcanols et procede pour les preparer |
| ES2569483T3 (es) * | 2007-06-21 | 2016-05-11 | Amgen Inc. | Métodos para sintetizar cinacalcet y sales del mismo |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| US8197858B2 (en) | 2009-02-06 | 2012-06-12 | Mark John Zamoyski | Bone microenvironment modulated seizure treatments |
| EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| UA113165C2 (xx) | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| TR201809351T4 (tr) | 2011-03-01 | 2018-07-23 | Pharnext | Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi. |
-
2014
- 2014-06-18 JP JP2016520456A patent/JP6476174B2/ja active Active
- 2014-06-18 SG SG11201510451RA patent/SG11201510451RA/en unknown
- 2014-06-18 PT PT147312615T patent/PT3010543T/pt unknown
- 2014-06-18 US US14/900,028 patent/US9789072B2/en active Active
- 2014-06-18 PL PL14731261.5T patent/PL3010543T3/pl unknown
- 2014-06-18 EP EP14731261.5A patent/EP3010543B1/en active Active
- 2014-06-18 MX MX2015018040A patent/MX366353B/es active IP Right Grant
- 2014-06-18 BR BR112015031835-5A patent/BR112015031835B1/pt active IP Right Grant
- 2014-06-18 DK DK14731261.5T patent/DK3010543T3/da active
- 2014-06-18 CA CA2915811A patent/CA2915811C/en active Active
- 2014-06-18 AU AU2014283319A patent/AU2014283319B2/en active Active
- 2014-06-18 ES ES14731261T patent/ES3053333T3/es active Active
- 2014-06-18 CN CN201480040973.6A patent/CN105658238B/zh active Active
- 2014-06-18 KR KR1020167001456A patent/KR102254542B1/ko active Active
- 2014-06-18 RU RU2016101152A patent/RU2685502C2/ru active
- 2014-06-18 WO PCT/EP2014/062786 patent/WO2014202646A1/en not_active Ceased
-
2015
- 2015-12-17 IL IL243192A patent/IL243192B/en active IP Right Grant
- 2015-12-18 CL CL2015003679A patent/CL2015003679A1/es unknown
-
2016
- 2016-01-14 ZA ZA2016/00312A patent/ZA201600312B/en unknown
-
2017
- 2017-09-22 US US15/713,372 patent/US20180042869A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES3053333T3 (en) | 2026-01-21 |
| BR112015031835A2 (pt) | 2017-07-25 |
| MX2015018040A (es) | 2016-08-03 |
| US20160158167A1 (en) | 2016-06-09 |
| BR112015031835A8 (pt) | 2019-12-31 |
| AU2014283319B2 (en) | 2019-07-25 |
| JP2016522235A (ja) | 2016-07-28 |
| CN105658238A (zh) | 2016-06-08 |
| EP3010543A1 (en) | 2016-04-27 |
| RU2685502C2 (ru) | 2019-04-19 |
| CN105658238B (zh) | 2019-07-12 |
| CA2915811C (en) | 2021-08-31 |
| NZ715951A (en) | 2021-03-26 |
| US9789072B2 (en) | 2017-10-17 |
| CL2015003679A1 (es) | 2016-09-02 |
| PT3010543T (pt) | 2025-11-28 |
| IL243192B (en) | 2019-12-31 |
| PL3010543T3 (pl) | 2026-01-19 |
| IL243192A0 (en) | 2016-02-29 |
| ZA201600312B (en) | 2022-12-21 |
| RU2016101152A (ru) | 2017-07-24 |
| JP6476174B2 (ja) | 2019-02-27 |
| MX366353B (es) | 2019-07-05 |
| US20180042869A1 (en) | 2018-02-15 |
| AU2014283319A1 (en) | 2016-02-11 |
| CA2915811A1 (en) | 2014-12-24 |
| DK3010543T3 (da) | 2025-12-01 |
| HK1223014A1 (zh) | 2017-07-21 |
| KR102254542B1 (ko) | 2021-05-24 |
| KR20160055121A (ko) | 2016-05-17 |
| EP3010543B1 (en) | 2025-11-05 |
| WO2014202646A1 (en) | 2014-12-24 |
| SG11201510451RA (en) | 2016-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI891942B (zh) | 氘化化合物 | |
| Nicholson et al. | Parkinson’s disease and anaesthesia | |
| JP2000500446A (ja) | 疼痛の処置のためのエピナスチンの使用 | |
| JP2016065108A (ja) | エキソ−ｓ−メカミラミン製剤および治療におけるその使用 | |
| US20180133209A1 (en) | Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| JPH01250315A (ja) | 脳機能改善剤 | |
| HU226138B1 (en) | R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof | |
| PT867179E (pt) | Composicao de esteres de l-dopa | |
| BR112021015600A2 (pt) | Métodos e composições para tratamento da apneia do sono | |
| BR112020004622A2 (pt) | pridopidina para tratamento de discinesias induzidas por droga | |
| JP2021138703A (ja) | オピオイドとｎ−アシルエタノールアミンの組み合わせ | |
| BR112015031835B1 (pt) | Usos de agentes terapêuticos, de uma combinação dos referidos agentes com um agente terapêutico adicional, e de uma composição farmacêutica para fabricação de medicamento para a profilaxia e/ou tratamento de distúrbios do movimento hipercinético | |
| IE843149L (en) | Synergistic pharmaceutical compositions | |
| JP2003321357A (ja) | 内服用組成物 | |
| US12447135B2 (en) | Fenchol as a stimulator of free fatty acid receptor and other uses thereof | |
| JP7744419B2 (ja) | レット症候群を治療するためのプリドピジンまたはその類似体の使用 | |
| NZ715951B2 (en) | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders | |
| CA3102826A1 (en) | Disease modifying methods for treating neurodegenerative diseases using nootropic agents | |
| CN117337183A (zh) | 富勒烯gaba多巴及方法 | |
| JP2022501419A (ja) | 鎮痛組成物 | |
| NZ259531A (en) | Use of idazoxan and derivatives (2-(1,4-benzodioxan-2-yl)-2-imidazoline) to prepare medicaments to treat alzheimer-type diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2014, OBSERVADAS AS CONDICOES LEGAIS |